Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 14/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | RIPK3 | Q9Y572 | 3/20 | 0.62 |
| ▸ | AXL | P30530 | 7/20 | 0.62 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.61 |
| ▸ | MERTK | Q12866 | 4/20 | 0.61 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | KIT | P10721 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | FLT3 | P36888 | 1/20 | 0.60 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681138 | 0.88 | AXL (0.61) | METCYP3A4CYP2C9RIPK3AXL | |
| SCHEMBL680387 | 0.87 | MET (0.62) | METCYP3A4CYP2C9RIPK3AXL | |
| SCHEMBL680235 | 0.86 | AXL (0.61) | METAXLTYRO3MERTKKDR | |
| SCHEMBL680709 | 0.85 | AXL (0.58) | METCYP3A4CYP2C9RIPK3AXL | |
| SCHEMBL701942 | 0.85 | AXL (0.57) | METCYP3A4CYP2C9RIPK3AXL | |
| SCHEMBL680640 | 0.84 | MET (0.55) | METCYP3A4CYP2C9RIPK3AXL | |
| SCHEMBL12190710 | 0.84 | AXL (0.66) | METCYP3A4CYP2C9RIPK3AXL | |
| SCHEMBL680684 | 0.84 | AXL (0.56) | METCYP3A4CYP2C9RIPK3AXL | |
| SCHEMBL680685 | 0.84 | AXL (0.56) | METCYP3A4CYP2C9RIPK3AXL | |
| SCHEMBL680268 | 0.83 | AXL (0.55) | METCYP3A4CYP2C9RIPK3AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43878-E1 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| US-RE43878-E1 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| US-RE43878-E1 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| US-8030302-B2 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030302-B2 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030302-B2 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| WO-2010011538-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY | 2010-01-28 | — | — | US | disclosed |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY | 2010-01-28 | — | — | US | disclosed |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | MET, MYCBP, MYC | MET 1/4885CYP3A4 1242/4885CYP2C9 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.